Latest news with #WatersCorporation
Yahoo
12 hours ago
- Business
- Yahoo
How Is Waters Corporation's Stock Performance Compared to Other Healthcare Stocks?
With a market cap of $20.2 billion, Waters Corporation (WAT) is a global leader in analytical instruments and laboratory solutions. Operating through its Waters and TA Divisions, the company designs, manufactures, and services high-performance liquid chromatography, mass spectrometry, and thermal analysis systems. Companies valued at more than $10 billion are generally considered 'large-cap' stocks, and Waters Corporation fits this criterion perfectly. Its innovative products support pharmaceutical, life science, industrial, and governmental customers across Asia, the Americas, and Europe in research, development, and quality assurance applications. OpenAI CEO Sam Altman Says 'We Are Heading Towards a World Where AI Will Just Have Unbelievable Context on Your Life' Archer Aviation Is Betting Big on Its Fledgling Defense Business. Does That Make ACHR Stock a Buy Here? Unusual Call Options Activity in Marvell Technology Highlights the Value of MRVL Stock Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Shares of the Milford, Massachusetts-based company have fallen 19.9% from its 52-week high of $423.56. Over the past three months, shares of WAT have declined 11.2%, underperforming the 9.3% dip of the Health Care Select Sector SPDR Fund (XLV) during the same period. Longer term, WAT stock is down 8.5% on a YTD basis, a steeper decline than XLV's 3.2% drop. However, shares of Waters Corporation have returned 15.3% over the past 52 weeks, surpassing XLV's 8.7% decline over the same time frame. The stock has been trading below its 200-day moving average since April. Despite reporting better-than-expected Q1 2025 adjusted EPS of $2.25 and revenue of $661.7 million, WAT shares fell 2.7% on May 6, likely due to investor concerns over macroeconomic uncertainties and tariff impacts. However, the company raised its full-year adjusted EPS guidance to $12.75 - $13.05 and constant currency sales growth to 5% - 7%. WAT stock has outperformed its rival, Thermo Fisher Scientific Inc. (TMO). TMO stock has fallen 31% over the past 52 weeks and 24.5% on a YTD basis. Despite the stock's outperformance over the past year, analysts are cautiously optimistic about its prospects. The stock has a consensus rating of 'Moderate Buy' from the 18 analysts covering the stock, and as of writing, it is trading below the mean price target of $393. On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
04-06-2025
- Health
- Yahoo
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass., June 4, 2025 /PRNewswire/ -- 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company's most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency. "Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape," said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. "The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers." Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance. Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing. "Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed," said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. "We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities." In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers. The Xevo TQ Absolute XR Mass Spectrometer is available to order now. Additional Resources Product Page Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic] View original content: SOURCE Waters Corporation Sign in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
News Summary Up to six-fold increase in performance robustness with StepWave™ XR Ion Guide versus Xevo TQ Absolute.1 Uses up to 50% less power and gas, and occupies up to 50% less bench space than other products in its class.2 Takes the industry-leading sensitivity of Xevo TQ Absolute to new heights, including for PFAS detection and pharma quantitation applications. BALTIMORE and MILFORD, Mass., June 2, 2025 /PRNewswire/ -- 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR Mass Spectrometer, the Company's most sensitive, robust, and reliable benchtop tandem quadrupole. Notably, the product exceeds the performance capabilities of the Xevo TQ Absolute, which itself set the benchmark in the industry for tandem quadrupole sensitivity, particularly in areas such as pharmaceutical quantitation and PFAS detection. Tailored for high-throughput applications in pharmaceutical companies, contract testing organizations, and government laboratories, the new system is designed to deliver exceptional performance for the most sensitive trace-level analyses in complex matrices, while maximizing system uptime and efficiency. "Analytical laboratories are under pressure to adapt to the complex needs of pharmaceutical organizations, and meet the increasing demand for PFAS testing driven by a rapidly evolving regulatory landscape," said James Hallam, Vice President, Liquid Chromatography-Mass Spectrometry, Waters Corporation. "The Xevo TQ Absolute XR design delivers up to a six-fold increase in performance robustness with unmatched sensitivity and resilience to contamination, significantly reducing downtime and enhancing operational efficiency for our customers." Built on the trusted, intuitive design of the Xevo TQ Absolute Mass Spectrometer, the Xevo TQ Absolute XR Mass Spectrometer offers significant operational efficiencies. It uses up to 50% less power and nitrogen gas, produces 50% less heat than any other high-performing tandem or triple quadrupole on the market, and takes up to 50% less bench space, making it the ideal system for laboratories striving to reduce their environmental footprint without compromising throughput or performance. Within the Xevo TQ Absolute XR Mass Spectrometer, Waters introduces the StepWave XR Ion Guide, which incorporates sophisticated technology designed to minimize the risk of unplanned downtime, while preserving high sensitivity and precision for even the most complex sample types and fragile compounds. Through this innovation, customers are realizing a new benchmark of robustness across a wide range of applications, including PFAS, bioanalysis, and genotoxic impurity testing. "Our laboratory requires instrumentation that delivers high-quality, interruption-free results to our customers, helping them to bring safe and effective new drugs to market with confidence and speed," said Sally Hannam, Scientific Director, Synexa Life Sciences, a leading biomarker and bioanalytical services provider. "We are well in excess of 20,000 injections of crashed human plasma continuously analyzed on the Xevo TQ Absolute XR Mass Spectrometer combined with the ACQUITY™ Premier UPLC™ System and waters_connect™ Software, and our early experience is that it demonstrates new levels of reproducibility and accuracy, giving us ever more confidence as we are presented with increasingly challenging bioanalysis applications and new modalities." In addition, the design of the Xevo TQ Absolute XR Mass Spectrometer delivers industry-leading, out-of-the-box quantitation of negatively ionizing compounds, such as PFAS. Bioanalytical, food safety, and environmental testing laboratories will benefit from the high confidence results and operational efficiency gains that the Xevo TQ Absolute XR Mass Spectrometer delivers. The Xevo TQ Absolute XR Mass Spectrometer is available to order now. Additional Resources Product Page Waters, StepWave, ACQUITY, UPLC, waters_connect, and Xevo are trademarks of Waters Technologies Corporation. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 Application Note on Product Webpage. In a well-controlled experiment, performance was maintained for up to six times the duration on the Xevo TQ Absolute XR compared to the Xevo TQ Absolute; more than 12,000 samples of pesticides in fish feed matrix were analyzed. Based on a comparison of high-end tandem and triple quadrupole instruments available on the market. [Infographic] View original content to download multimedia: SOURCE Waters Corporation
Associated Press
28-05-2025
- Business
- Associated Press
Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality
News Summary MILFORD, Mass., May 28, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements. This launch marks the first set of affinity chromatography columns that Waters has brought to market, in a groundbreaking move as the Company continues to release new products that solve unmet needs in large molecule separations. The new columns enable earlier access to results in upstream bioprocessing, faster method optimization in downstream development for biologics, and a new level of agility in the discovery, optimization, and manufacturing of antibody-based drug products. 'Today's launch of the BioResolve Protein A Affinity Columns will help to bring lifesaving therapies to patients, faster. One of the main bottlenecks in the development of biotherapeutics like monoclonal antibodies is the time required to identify and optimize a suitable cell line for antibody production,' said Dr. Udit Batra, President and Chief Executive Officer, Waters Corporation. 'We have solved for this by designing a novel, highly efficient particle with an immobilized Protein A surface, and combined this with MaxPeak Premier Hardware, resulting in the most sensitive protein A column on the market.' The BioResolve Protein A Affinity Columns have been designed to provide up to 7x improvements in sensitivity compared to the market leader. The novel, non-porous 3.5 μm particles allow accurate quantitation of antibody titers at lower concentrations and with less sample. In addition, the columns have been designed to couple with size exclusion chromatography columns to measure titer concentrations and aggregate analysis in a single run on any LC system. 'The new column will enhance our ability to support our clients in developing new medicines,' said Arnaud Delobel, R&D and Innovation Director, Quality Assistance. 'It simplifies two-dimensional workflows for simultaneous titer and aggregate analysis, and can be readily integrated into new LC/MS setups to analyze in-process antibody samples without prior purification. By streamlining workflows and enabling simultaneous assessment of multiple critical quality attributes, it helps cut project turnaround times and ultimately supports faster time to market for biologics.' This innovation furthers the Company's commitment to enhancing the analytical toolbox for biomolecule characterization, allowing scientists to speed up the development of safe, efficacious, and accessible biotherapeutics. The columns are available in 2.1 x 20 mm and 3.9 x 5 mm formats and are available to order now. Additional Resources: See application notes and specifications at ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Waters, BioResolve, and MaxPeak are trademarks of Waters Technologies Corporation. Contact: Molly Gluck Head of External Communications Waters Corporation [email protected] Mobile: +1.617.833.8166 View original content to download multimedia: SOURCE Waters Corporation
Yahoo
13-05-2025
- Business
- Yahoo
Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance
News Summary Saves up to six months on compliant software validation in biopharmaceutical quality control.1 Reduces analysis time for biotherapeutic peptides and proteins by 20%.2 Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.3 MILFORD, Mass., May 13, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attributes that a biopharmaceutical laboratory can manage using Empower Software. Additionally, this advancement will simplify the process and digital footprint of acquiring and submitting compliant data to regulatory authorities – from biologics development through QC – saving customers up to six months of software validation time. Empower Software is the industry's most established and compliant-ready chromatography data system (CDS), widely adopted globally and used to submit data for more than 80% of novel drugs to regulatory authorities.4 The new integration unlocks the ability to use MALS techniques in quality control for biotherapeutics, improving efficiency and Good Manufacturing Practices (GMP) readiness, while reducing end-user training in compliant settings. "Today's launch of Empower for Multi-Angle Light Scattering Detectors underscores our commitment from the Wyatt acquisition to integrate advanced analytical technologies into our Empower CDS ecosystem," said Dr. Udit Batra, President & CEO, Waters Corporation. "Specifically, MALS supported on Empower Software reveals high molecular weight species that are not visible to other detectors – reducing the risk of erroneous results in biotherapeutic quality control. By combining the strengths of compliant software with deep analytical light scattering instrumentation, we are providing customers with a unified solution that enhances productivity and data accuracy – ultimately supporting high-volume QC testing to ensure the safety of life-saving biologic therapies for patients." The integration of the DAWN™, miniDAWN™, and OptiLab™ Detectors will enable the measurement of more critical quality attributes of peptides and proteins in a single run, reducing analysis time by 20% and providing earlier insights into the stability, safety, and efficacy of biologics. "As a Contract Development and Manufacturing Organization (CDMO), we anticipate that MALS on Empower Software will enhance our service offerings," said William Wittbold, Senior Director of Operations, at Pace Analytical. "The detailed MALS data is essential for understanding complex biotherapeutics. Combined with the reliability of Empower Software, we believe this integration will deliver exceptional value to our customers, ensuring our drug development partners receive the highest quality results." The capability to integrate the DAWN, miniDAWN, and OptiLab Detectors with Empower Software will be available for peptide and protein workflows in July 2025. Learn more by visiting our product page. Additional Resources - Learn more about the MALS integration with Empower Software. - Follow and connect with Waters LinkedIn, Twitter, and Facebook. ABOUT: Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science. Waters, Empower, DAWN, miniDAWN, OptiLab, and Wyatt Technology are trademarks of Waters Technologies Corporation. Contact: Molly GluckHead of External CommunicationsWaters Corporationmolly_gluck@ +1.617.833.8166 1. In a recent survey of 50 MALS users, responding to the question "How long does it typically take you to validate new software in a GxP lab," the average time was reported as 6 months since it is one software instead of two. 2. In a recent survey of 50 MALS users, responding to the question "How much time, as a percentage of total working time, would you save on average if you could use your primary CDS software (LC software) for MALS data analysis," the average time saving was reported as 20%. 3. White paper WP1615: "SEC-MALS for absolute biophysical characterization" describes the challenges associated with determining basic physical properties of biologics in solution, and provides examples of how multi-angle light scattering can reduce the occurrence of erroneous results prevalent in relative measurement techniques. MALS provides absolute results from first principles, avoiding errors of relative measures, and is independent of retention time, reference materials, and column interactions. 4. Presented at the J.P. Morgan 43rd Annual Healthcare Conference. According to internal analysis, ~80% of the drugs filed with the FDA, EMA, and China National Medical Products Administration (NMPA) in 2023 were done so using Empower Software. Source: Waters data and estimates. View original content: SOURCE Waters Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
